1. Early evidence of dose-dependent pharmacodynamic activity following treatment with SY-5609, a highly selective and potent oral CDK7 inhibitor, in patients with advanced solid tumors. (October 2020) Authors: Papadopoulos, K.; Sharma, M.; Hamilton, E.; Richardson, D.; Bashir, B.; Hodgson, G.; Ke, N.; Kang-Fortner, Q.; Zhou, L.; Zamboni, W.; Jolin, H.; Madigan, C.; Kelly, M.; Roth, D. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P492: TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED ADULT PATIENTS SELECTED FOR RARA-POSITIVE AML WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY (SELECT AML-1). (23rd June 2022) Authors: Stein, E.; de Botton, S.; Pigneux, A.; McMahon, C.; Ball, B.; Borthakur, G.; Eghtedar, A.; Kambhampati, S.; Tache, J.; Wang, E.; Kelley, H.; Volkert, A.; Baker, K.; Kang-Fortner, Q.; Hodgson, G.; Madigan, C.; Warlick, E.; Roth, D.; Kelly, M.; Pollyea, D. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 391 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1). (23rd June 2022) Authors: DeZern, A.; Marconi, G.; Deeren, D.; Diez Campelo, M.; Lübbert, M.; Krishnamurthy, P.; Nagy, Z.; Basak, G.; Jonášová, A.; Morozova, E.; Geissler, K.; Ofran, Y.; Kelley, H.; Volkert, A.; Baker, K.; Kang-Fortner, Q.; Hodgson, G.; Madigan, C.; Roth, D. A.; Kelly, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1800 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗